Investigational Products

SALIX is committed to the development of innovative treatments for gastrointestinal (GI) diseases and other disorders that provide healthcare professionals (HCPs) and patients with effective treatment options.

Details for the molecules currently included in our pipeline are provided in the table below. See table footnotes for links to individual clinical trial information.

Image showing development phase of pipeline products

*For more information on clinical trials of rifaximin soluble solid dispersion in hepatic encephalopathy, click here or click here.

†For more information on clinical trials of rifaximin extended-release/delayed extended-release tablets in sickle cell disease, click here.

‡To view new data presented at Digestive Disease Week (DDW) 2024 on the phase 2 results for amiselimod for the treatment of active ulcerative colitis, click here.

For more information on clinical trials of amiselimod in mild to moderate ulcerative colitis, click here.

This page was last updated on July 15, 2024. The safety and efficacy of these investigational products have not been established.

There is no guarantee that the outcomes of the studies shown here will result in approval by a regulatory authority.

Approved Products

Learn about Salix products approved for use by the US Food and Drug Administration (FDA).

VIEW MORE

Search

*Required field.

Select a product*

Select

Select a therapeutic area*

Select

Enter keyword(s)